| Summary: | Diabetes mellitus and dyslipidemia are major risk factors of coronary heart disease (CHD). Statin drugs have become
the first-line drug therapy for diabetic dyslipidemia. This study evaluated the cost-effectiveness of statin monotherapy by
comparing Simvastatin, Atorvastatin, Rosuvastatin, Fluvastatin and Pravastatin in diabetes patients at Phramongkutklao
Hospital. Statin effectiveness and cost-effectiveness in attaining low-density lipoprotein cholesterol (LDL-C) goal was evaluated.
The result showed that, of 923 eligible patients, Simvastatin had the lowest mean annualized treatment cost and was the
most effective statin, as indicated by the CER and the ICER, among outpatients with diabetes compared with other statins in
this study
|
|---|